Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

19 Apr 2011

Abstract excerpt

We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to HIV Research and Treatment
Share to Malaria Research and Control

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21501642
DOI: 10.1016/j.vaccine.2011.03.083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccinePMID 21501642Read ↗

Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length<i>Plasmodium falciparum</i>Circumsporozoite ProteinSemantic proximity Read ↗

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adultsSemantic proximity Read ↗

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adultsSemantic proximity Read ↗

Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28—evaluation of homologous and heterologous antigen-delivery prime-boost strategySemantic proximity Read ↗

Progress in DNA‐based heterologous prime‐boost immunization strategies for malariaSemantic proximity Read ↗

Malaria Vaccine: Candidate Antigens, Mechanisms, Constraints and ProspectsSemantic proximity Read ↗

Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future DirectionsSemantic proximity Read ↗

Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteersSemantic proximity Read ↗

New Candidate Vaccines against Blood-StagePlasmodium falciparumMalaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1Semantic proximity Read ↗

A protein particle vaccine containing multiple malaria epitopesSemantic proximity Read ↗

Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy VolunteersSemantic proximity Read ↗

Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.